Ireland
--:--IST
Recruiting Observational

TREAT NL (TREatment of ATopic Eczema, the Netherlands) Registry: Dutch National Registry for Patients With Moderate-to-severe Atopic Eczema on Photo- or Systemic Therapies

NCT03621137 · tracked via the Priya Life Science Netherlands tracker
Phase
Observational
Started
2017-11-01
Last updated
2024-01-31

Condition(s) studied

Moderate-to-severe Atopic Eczema

Investigational drug(s) / intervention(s)

No study-specific intervention

No study-specific intervention: Treatment of atopic eczema with phototherapy or systemic immunomodulating therapy according to usual clinical practice

Study summary

The TREAT NL (TREatment of ATopic eczema, the Netherlands) registry is a national registry for children and adults with moderate-to-severe atopic eczema aiming to gather data on their prescribed photo- and systemic immunomodulating therapies. Atopic eczema is a common, chronic, itchy, inflammatory skin disease that can have a major impact on the quality of life of patients and their immediate surroundings.

Serious atopic eczema patients are treated by means of photo- or systemic immunomodulating therapy. Of these mostly off-label applied therapies, there is insufficient evidence on the short and long term for their effectiveness, safety and cost-effectiveness. Moreover, good comparative research and real-life data are lacking. With the arrival of new expensive treatments it is crucial to get insight into these treatments in order to improve quality of care.

By means of a prospective registry these data can be collected and help to obtain information for clinical practice, for answering research questions, for reducing costs and implementing the results by guidelines and decision aids.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient has a diagnosis of atopic eczema, based on the U.K. working party's diagnostic criteria; * Starts with any type of phototherapy (e.g. UVB) or systemic immunomodulating therapy (e.g. cyclosporin, systemic glucocorticosteroids, azathioprine, methotrexate, mycophenolic acid, dupilumab); * Has voluntarily signed and dated an informed consent prior to any study related procedure or has a legal representative to do so and is willing to comply with the requirements of this study protocol. Exclusion Criteria: * Patient uses only (systemic) antibiotics or antihistamines; * Patient starts with systemic immunomodulating therapy for another indication than atopic eczema; * Insufficient understanding of the study by the patient or parent/legal representative.

Primary outcome measure(s)

  • Mean change in EASI (Eczema Area and Severity Index) score — 5 years
    Investigator-assessed outcome measure for disease severity at physical examination
  • Mean change in IGA (Investigator's Global Assessment) score — 5 years
    Investigator-assessed outcome measure for global disease severity
  • Mean change in POEM (Patient-Oriented Eczema Measure) score — 5 years
    Patient-reported outcome measure for symptoms of atopic eczema
  • Mean change in PGA (Patient's Global Assessment) score — 5 years
    Patient-reported outcome measure for global disease severity
  • Mean change in DLQI (Dermatology Life Quality Index) score — 5 years
    Patient-reported outcome measure for skin-related quality of life
  • Mean time to reach a change in EASI (Eczema Area and Severity Index) score of 50% — 5 years
    Investigator-assessed outcome measure for disease severity at physical examination
  • The occurrence of severe adverse events — 5 years
    Any undesirable experience of severe nature occurring to a subject is reported
  • Drug survival of the therapies — 5 years
    Assessment of the duration until discontinuation of a drug together with the reason thereof

Trial sites (1)

FacilityCityRegionStatus
Department of Dermatology, Amsterdam University Medical Centres, University of Amsterdam, Research Institute Amsterdam Public Health and Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands Amsterdam North Holland Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03621137 on ClinicalTrials.gov ↗ ← All trials in the Netherlands